DK3589655T3 - Tandem diabody til cd16a målrettet nk-celle optagelse - Google Patents

Tandem diabody til cd16a målrettet nk-celle optagelse Download PDF

Info

Publication number
DK3589655T3
DK3589655T3 DK18708967.7T DK18708967T DK3589655T3 DK 3589655 T3 DK3589655 T3 DK 3589655T3 DK 18708967 T DK18708967 T DK 18708967T DK 3589655 T3 DK3589655 T3 DK 3589655T3
Authority
DK
Denmark
Prior art keywords
cd16a
targeted
cell capture
tandem diabody
diabody
Prior art date
Application number
DK18708967.7T
Other languages
Danish (da)
English (en)
Inventor
Ivica Fucek
Uwe Reusch
Martin Treder
Stefan Knackmuss
Erich Rajkovic
Kristina Ellwanger
Michael Weichel
Thorsten Ross
Original Assignee
Affimed Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affimed Gmbh filed Critical Affimed Gmbh
Application granted granted Critical
Publication of DK3589655T3 publication Critical patent/DK3589655T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/30Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565Complementarity determining region [CDR]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622Single chain antibody (scFv)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/60Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/626Diabody or triabody
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/90Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK18708967.7T 2017-02-28 2018-02-28 Tandem diabody til cd16a målrettet nk-celle optagelse DK3589655T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP17158566 2017-02-28
EP17174407 2017-06-02
PCT/EP2018/054989 WO2018158349A1 (en) 2017-02-28 2018-02-28 Tandem diabody for cd16a-directed nk-cell engagement

Publications (1)

Publication Number Publication Date
DK3589655T3 true DK3589655T3 (da) 2022-11-28

Family

ID=61569251

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18708967.7T DK3589655T3 (da) 2017-02-28 2018-02-28 Tandem diabody til cd16a målrettet nk-celle optagelse

Country Status (8)

Country Link
US (2) US11180558B2 (enExample)
EP (1) EP3589655B1 (enExample)
JP (1) JP7115758B2 (enExample)
CN (1) CN110382539B (enExample)
AU (1) AU2018228719B2 (enExample)
CA (1) CA3051062C (enExample)
DK (1) DK3589655T3 (enExample)
WO (1) WO2018158349A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20200143436A (ko) 2018-04-13 2020-12-23 아피메트 게엠베하 Nk 세포 결합 항체 융합 구조체
AU2021357841A1 (en) * 2020-10-08 2023-06-15 Affimed Gmbh Trispecific binders
CR20230229A (es) * 2020-11-06 2023-09-05 Amgen Res Munich Gmbh Moléculas de unión a antígeno biespecíficas con múltiples dianas de selectividad aumentada
WO2022161314A1 (zh) * 2021-01-27 2022-08-04 信达生物制药(苏州)有限公司 针对cd16a的单域抗体及其用途
CN117580865A (zh) * 2021-06-29 2024-02-20 山东先声生物制药有限公司 Cd16抗体及其应用
WO2023079493A1 (en) * 2021-11-03 2023-05-11 Affimed Gmbh Bispecific cd16a binders
EP4426439A1 (en) * 2021-11-03 2024-09-11 Affimed GmbH Bispecific cd16a binders
CN114262382B (zh) * 2021-12-20 2023-09-19 上海恩凯细胞技术有限公司 双特异性抗体及其应用
EP4572772A1 (en) 2022-08-17 2025-06-25 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
CN115960234B (zh) * 2022-10-27 2023-12-29 合肥天港免疫药物有限公司 抗cd16a的抗体及其应用
WO2024131731A1 (zh) 2022-12-19 2024-06-27 和铂医药(上海)有限责任公司 "κ/λ"Fab-Fab串联多特异性结合蛋白及其制备和应用
WO2024249954A1 (en) 2023-05-31 2024-12-05 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
WO2025076127A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19819846B4 (de) * 1998-05-05 2016-11-24 Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts Multivalente Antikörper-Konstrukte
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
DE60127143T2 (de) * 2001-11-14 2007-11-15 Affimed Therapeutics Ag Bispezifische Antikörper gegen CD19 und CD16 und deren Verwendung
GB0510790D0 (en) * 2005-05-26 2005-06-29 Syngenta Crop Protection Ag Anti-CD16 binding molecules
KR101799337B1 (ko) * 2007-06-21 2017-12-20 마크로제닉스, 인크. 공유결합형 디아바디 및 이것의 사용
SI2406284T1 (sl) 2009-03-10 2017-01-31 Biogen Ma Inc. Anti-bcma protitelesa
US20110206672A1 (en) * 2010-02-25 2011-08-25 Melvyn Little Antigen-Binding Molecule And Uses Thereof
PT2361936T (pt) * 2010-02-25 2016-07-15 Affimed Gmbh Molécula que se liga a antigénio e utilizações desta
US20140105915A1 (en) 2011-05-27 2014-04-17 Glaxo Group Limited Bcma (cd269/tnfrsf17) - binding proteins
CN103687879B (zh) * 2011-07-22 2016-05-04 阿菲姆德农业医药公司 多价抗原结合fv分子
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對bcma之e3以及cd3的結合分子
CA2889764C (en) 2012-11-01 2023-10-10 Martin Lipp An antibody that binds cd269 (bcma) suitable for use in the treatment of plasma cell diseases such as multiple myeloma and autoimmune diseases
JP2016507523A (ja) 2013-02-05 2016-03-10 エンクマフ アーゲー CD3εおよびBCMAに対する二重特異的抗体
AR095374A1 (es) 2013-03-15 2015-10-14 Amgen Res Munich Gmbh Moléculas de unión para bcma y cd3
SI3030581T1 (sl) * 2013-08-07 2021-07-30 Affimed Gmbh Mesta za vezavo na protitelo, ki so specifična za EGFRVIII
GB201505305D0 (en) 2015-03-27 2015-05-13 Immatics Biotechnologies Gmbh Novel Peptides and combination of peptides for use in immunotherapy against various tumors
RS59489B1 (sr) * 2015-05-04 2019-12-31 Affimed Gmbh Kombinacija anti-cd30xcd16a antitela sa antagonističkim anti-pd-1 antitelom za terapiju
CN105367660B (zh) * 2015-12-22 2018-12-21 深圳市北科生物科技有限公司 一种抗cd16a抗原和抗muc1抗原的双特异性抗体

Also Published As

Publication number Publication date
AU2018228719A1 (en) 2019-08-08
US20190345249A1 (en) 2019-11-14
JP2020510659A (ja) 2020-04-09
US20220041717A1 (en) 2022-02-10
WO2018158349A1 (en) 2018-09-07
AU2018228719B2 (en) 2023-03-30
US12264198B2 (en) 2025-04-01
CN110382539A (zh) 2019-10-25
JP7115758B2 (ja) 2022-08-09
US11180558B2 (en) 2021-11-23
CA3051062A1 (en) 2018-09-07
EP3589655A1 (en) 2020-01-08
CN110382539B (zh) 2023-08-08
CA3051062C (en) 2023-09-26
EP3589655B1 (en) 2022-10-26

Similar Documents

Publication Publication Date Title
DK3589655T3 (da) Tandem diabody til cd16a målrettet nk-celle optagelse
DK3177484T3 (da) Forbedret kommunikationssystem til køretøjskatastrofeblink
PT4219542T (pt) Recetores de células t
PT3440106T (pt) Recetores de células t
CL2018000281A1 (es) Anticuerpos monoclonales contra bcma
DK3368101T3 (da) Autoinjektor til engangsbrug
DK3266792T3 (da) Fremgangsmåde til peptidsyntese
DK3393512T3 (da) Rsv f-proteinmutanter
EP3580354A4 (en) HIGH FLOW SINGLE-CELL POLYOMIC
DK3215601T3 (da) Fremgangsmåder til transduktion og celleforarbejdning
DK3352625T3 (da) Reorganiserbar liggestol til flere formål, flere anvendelser
DK3397294T3 (da) Fremgangsmåde til fremstilling af 3d-bruskorganoidblok
IL255626B (en) Nutrient system
BR112018006551A2 (pt) conjunto de porca bipartida
ZA201603750B (en) Method and system for assessing performance of arbitrarily large arrays
DK3525733T3 (da) Indføringsenhed til intrauterint system
DK3596379T3 (da) Fremstillingsfremgangsmåde til katodisk beskyttelse
DK3038204T3 (da) Antenneenhed til høreapparat
DK3512536T3 (da) Pd-1-peptidinhibitorer
FR3042832B1 (fr) Ecrou etanche
DK3640164T3 (da) Justerbare transportørsystemer
EP3380824C0 (en) LOW VOLUME MULTIPASS CELL
EP3397108A4 (en) LOAD-LOADING SYSTEMS
FR3023067B1 (fr) Cellules tandem multifils
FI20160105A7 (fi) Menetelmä käyttäytymiskokeiden suorittamiseksi jyrsijöillä